← GLP-1 receptor agonists × adverse events & safety

SynthesisClinical and translational science2025

Once-Weekly Semaglutide Versus Once-Daily Liraglutide for Weight Loss in Adults: A Meta-Analysis of Randomized Controlled Trials.

Tallal Mushtaq Hashmi et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 922 people · 2025

Range includes no effect

No clear effect on adverse events & safety

1.7×0.5× to 5.2×

Bigger than 7 in 10 for adverse events & safety

As reported

OR 1.66, 95% CI 0.53–5.16

Range includes no effect

No clear effect on adverse events & safety

1.8×0.8× to 4.1×

Bigger than 8 in 10 for adverse events & safety

As reported

OR 1.84, 95% CI 0.82–4.14

Two numbers in the abstract

the abstract, start to end

The risk of severe adverse effects (OR, 1.66; 95% CI, 0.53-5.16; p = 0.38) and gastrointestinal adverse effects (OR, 1.84; 95% CI, 0.82-4.14; p = 0.14) …

← favours treatmentfavours comparator →
could be chance
Adverse events & safety
OR 1.660.53–5.16
Adverse events & safety
OR 1.840.82–4.14
GLP-1 receptor agonistsAdverse events & safety
1 / 3

6 papers cite it

2025
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 39930946